Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Plozasiran sodium by Arrowhead Pharmaceuticals for Familial Chylomicronemia (Type I Hyperlipoproteinemia): Likelihood of Approval
Plozasiran sodium is under clinical development by Arrowhead Pharmaceuticals and currently in Pre-Registration for Familial Chylomicronemia (Type I Hyperlipoproteinemia). According...
Plozasiran sodium by Arrowhead Pharmaceuticals for Hypertriglyceridemia: Likelihood of Approval
Plozasiran sodium is under clinical development by Arrowhead Pharmaceuticals and currently in Phase III for Hypertriglyceridemia. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Arrowhead Pharmaceuticals's Plozasiran sodium?
Plozasiran sodium is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase III program in Familial Chylomicronemia...